Biogen Idec Incorporated

Biogen, AbbVie drug slows MS episodes, safety issues reoccur

A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc., but serious infections and potential liver toxicity continued to cloud the drug's future.

The mixed results were seen in a Phase III international study of the medicine, called daclizumab, that involved more than 1,800 patients with relapsing-remitting multiple sclerosis -- the most common form of MS which can lead to disability and paralysis.

The companies disclosed partial results from the new trial on Monday. Shares of both Biogen and AbbVie were little changed in morning trading.

In the...